Pay in 4 interest-free payments of $5.30 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
doi: 10.1001/archopht.125.12.1652 31 TsaiC-CWuS-BChengC-YKaoS-CKauH-CLeeS-Met al
FIGURE 4 4 Comparative overview of mainstream GLP-1RAs Over the past 2 decades, several GLP-1RAs have entered clinical practice, including short-acting exenatide, intermediate-acting liraglutide, and long-acting formulations such as dulaglutide and semaglutide, as well as the newer dual agonist tirzepatide
Therefore, rising geriatric population is expected to drive the GLP-1 receptor agonist market during the forecast period
PMID: 41823054 Panou T et al
J Nutr Biochem 22:118694
US$ 24.51
US$ 25.49
US$ 23.52
US$ 21.12
US$ 28.78
US$ 22.02
